Canadian application, no grantCanada
Thymus-based tolerogenic approaches for type i diabetes
CA 2496692 A1 · Owner: Universite De Liege · Inventors: Geenen, Vincent
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides compositions and methods for the treatment and prevention of type I diabetes, comprising IGF-2 peptide.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 28, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 28, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 28, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledAugust 28, 2003
GrantedNo grant recorded
Term endedAugust 28, 2023
Patent numberCA 2496692 A1
Classification (IPC)A61K38/30 +1 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.